Cytospire is a startup based in the United Kingdom, most recent round Series A.
Cytospire is a company headquartered in the United Kingdom. Its most recent tracked round is Series A.
Cytospire develops next-generation multispecific antibodies that engage γδ T cells to create safer and more targeted cancer immunotherapies.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.